ClinicalTrials.gg

Program

zovegalisib

Its studies are mostly in Lymphatic Abnormalities · Breast Neoplasms, led by Relay Therapeutics.

Furthest: phase 2, since Jan 17, 20252 company-led studies, 2 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Relay Therapeutics22 open or runningphase 2since Jan 17, 2025Dec 20, 2021Apr 30, 2027phase 1 · NCT05216432

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2021First study: phase 1 study in Breast NeoplasmsFirst studyNCT05216432 · 930 planned · United States, Australia, France and more
  2. Jan 17, 2025Phase 2 study in Lymphatic AbnormalitiesNCT06789913 · 277 planned · United States, Australia, Belgium and more

Ahead

  1. Apr 30, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT05216432
  2. Jul 2031Primary completion: phase 2 study in Lymphatic AbnormalitiesNCT06789913

TargetBeta

PIK3CA →read by rule
“An orally bioavailable, pan-mutant selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (phosphoinositide 3-kinase alpha; PIK3CA; PI3K p110alpha), ”NCIt, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
AlpelisibruleNovartisphase 437
inavolisibruleHoffmann-La Rochephase 320
tersolisibEli Lillyphase 310
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
serabelisibruleTakedaphase 211
paxalisibrulekazia-therapeutics-limitedphase 24
risovalisibruleHaihe Biopharmaphase 24
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleensem-therapeuticsphase 21
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 11
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06789913Lymphatic Abnormalities · United States, Australia, Belgium and more2RecruitingJul 2031277
NCT05216432Breast Neoplasms · United States, Australia, France and more1RecruitingApr 30, 2027930

How it is read

Names in the registry

  • “RLY-2608”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.